Concurrent Investment Advisors LLC Has $11.38 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Posted by Francis Steltz on Sep 5th, 2026

Concurrent Investment Advisors LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 139.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,699 shares of the medical research company’s stock after acquiring an additional 13,232 shares during the period. Concurrent Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $11,380,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Bank OZK purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $1,096,000. Ausdal Financial Partners Inc. bought a new position in Thermo Fisher Scientific during the second quarter worth about $456,000. North Dakota State Investment Board purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $7,505,000. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $15,501,867,000. Finally, German American Bancorp Inc. bought a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $4,920,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Barclays increased their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 28th. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, CLSA initiated coverage on shares of Thermo Fisher Scientific in a report on Thursday. They issued an “outperform” rating and a C$748.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Get Our Latest Research Report on Thermo Fisher Scientific

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 275 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. This trade represents a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 over the last 90 days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.9%

Shares of NYSE:TMO opened at $612.75 on Friday. The firm has a fifty day moving average of $570.91 and a 200 day moving average of $515.10. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm has a market capitalization of $226.56 billion, a PE ratio of 32.96, a price-to-earnings-growth ratio of 2.59 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company’s revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.